ABSTRACT The phospholipid platelet-activating factor (PAF) stimulates platelet aggregation and coronary vasoconstriction. In this study we determined whether PAF alters coronary flow patterns in vivo in a canine preparation with concentric coronary artery stenosis. This preparation is characterized by cyclic flow variations in coronary blood flow associated with transient platelet aggregation at the site of the coronary constriction. Thirty-nine male mongrel dogs were used in three protocols. In protocol I, PAF (10-9 or 10-1 mol/min) was infused into the coronary artery proximal to the stenosis to determine (1) whether PAF induces cyclic flow variations and (2) whether PAF has an effect on systemic hemodynamics. Cyclic flow variations were induced in three of six dogs; in these animals, mean arterial pressure decreased by 5.5 % and 42. 1I% 10 min after infusion of the lower and higher dose of PAF. In protocol 2, cyclic flow variations were abolished with either the thromboxane synthetase inhibitor UK38485 (mean dose 2.2 mg/kg iv), the serotonin antagonist ketanserin (0.5 mg/kg iv), or the ca,-adrenergic antagonist yohimbine (2 mg/kg iv). 
sis. Platelet aggregates may mechanically obstruct an artery or may synthesize and release vasoactive agents such as thromboxane (Tx) A,, which has vasoconstrictor properties. Hirsh et al. ' found elevated coronary sinus-to-aortic ratios of TxB1, the stable metabolite of TxA,, in patients with unstable angina pectoris. Folts et al. ' developed an experimental preparation of a concentrically stenosed canine coronary artery. In this preparation there are episodic. spontaneous decreases in coronary blood flow interrupted by restora- tions of blood flow. These alterations in coronary blood flow have been called cyclic flow variations, which are associated with microscopic thrombi composed of platelets, erythrocytes, and leukocytes' 4 and with endothelial damage at the site of coronary arterial narrowing.4' We have shown that TxB, concentrations increase in the distal portion of the stenosed coronary artery and that an inhibitor of thromboxane synthetase, dazoxiben, abolishes cyclic flow variations and decreases the TxB, concentration measured distal to the stenosis. Similarly, serotonin or ae,adrenergic antagonists attenuate the frequency of cyclic flow variations.< Taken together, these data suggest that platelet-derived agents that alter platelet aggregation and vascular tone may mediate cyclic flow variations either alone or in concert. It is possible that thromboxane, serotonin, and a_-adrenergic receptor mechanisms are only some of the mediators of platelet activation in this experimental preparation; other agents may also influence platelet aggregation in the coronary circulation with resulting changes in coronary vascular tone and cyclic flow variations.
In this study we evaluated the recently isolated phospholipid 1 --hexadecyl-2-acetyl-sn-glyceryl-phosphorylcholine. or platelet-activating factor (PAF).
PAF stimulates human platelet aggregation in vitro7-9 and is released by human platelets"' and leukocvtes." It is a potent peripheral vasodilator' and decreases coronary blood flow when given by intracoronarv injection in the pig.) Because of these physiologic effects, we wished to determine (1) In all animals the placement of the catheter was checked with the infusion of 2. ml of monastral blue dye in 10 ml of saline through the diagonal branch catheter. Dogs in which the dye did not stain the area of coronary constriction and the distal LAD bed were excluded from subsequent analysis.
PAF-induced platelet aggregation in vitro. To further evaluate the mechanism of PAF-induced platelet aggregation. studies were performed on blood from seven of the dogs instrumented as described in the above protocols. Alter instrumentation but before any drugs. 45 ml of blood was obtained from the jugular venous catheter and transferred to a tube containing 5ml of 3.5%. sodium citrate, pH 7.4. The blood samples were centrifuged at 100 g for 20 min, resulting in a plasma suspension of platelets containing 300,000 to 500,000 platelets/mnm3. After removing the platelet-rich plasma. the remaining blood was centrifuged at 1500 g for 1(0 min to obtain platelet-poor plasma. Platelet aggregation was measured in vitro with a Sienco (Model DP 247-E) dual-channel aggregomaleter by the turbidomiietric method of Born. 1 The rate and extent of aceurecation in response to various concentrations of PAF were measured in a reaction volume of 500 gl of platelet-rich plasnma. Five minutes after the addition of PAF, a 50 gAl sanmple was remlloved from the aggregation cuvette and diluted into 450 gl of ice-cold distilled water containing indomethacin 10'>M. These samples were subsequently assayed for TxB1. In a separate set of experiments, platelet-rich plasma was preincubated with UK38485 (10-5M) for 3 min before the addition of PAF.
Prostaglandin measurements. TxB, and 6-keto PGF1, were measured by the method of Dray et 
Results
Hemodynamic data. PAF (10-1 mol/min) produced a significant decrease in aortic systolic, diastolic, and mean blood pressures (all p < .001) (table 1). After 10 min of infusion of PAF 10-x mol/min, the systolic, diastolic, and mean pressures were 59.9 + 8.5, 43.7 ± 5.6, and 49.0 ± 6.5 mm Hg, respectively, compared with control values of 97.7 ± 7.0, 80. 1 + 6.7, and 86.0 ± 6.7 mm Hg (figure 2). Because of the marked changes in systemic blood pressure, no attempt was made to evaluate coronary blood flow. Subsequent studies were performed with aortic pressure controlled by an aortic constrictor (table 2) .
There were no major hemodynamic effects of the thromboxane synthetase inhibitor UK38485 (table 2).
In the dogs given ketanserin, control blood pressure was reduced (p < .05) compared with the pretreatment value. Treatment with ketanserin had no other major hemodynamic effects (table 3 ). In the yohimbine-treated dogs there were no significant changes in systolic blood pressure (table 4) . There were no other consistent changes in any hemodynamic variable in the yohimbine-treated dogs. was used to quantitate the cyclic flow variations for the different times involved in the three phases of the protocol. Dogs were grouped according to the final treatment they received, i.e., the vehicle or PAF. The frequency of cyclic flow variations during control was identical in the two treatment groups (5.6 ± 0.6 vs 5. To evaluate potential hemodynamic differences between the initial and PAF-induced cyclic flow variations, the mean coronary blood flows at the nadir of flows were averaged during the initial cyclic flow variations and after the infusion of UK38485. PAF-induced aggregation of canine platelets in vitro at concentrations between 10`and 10-6M. With the platelet aggregation there was stimulation of the synthesis of TxB,, which was also concentration related.
In the platelet-rich plasma suspensions preincubated with UK38485 at 10-M, platelet aggregation still occurred with PAF, but there was no detectable increase in thromboxane synthesis.
Discussion PAF is a member of a recently described phospholipid family with potent hypotensive'" and platelet-aggregating properties.8 PAF causes bronchospasm in the guinea pig20 and its release is postulated to be a mechanism for inducing asthma.2' Human leukocytes release PAF" when stimulated by immune complexes. Human and rabbit platelets form PAF when stimulated with the calcium ionophore A23187,2' as do human endothelial cells in culture.2 Previous histologic studies of canine coronary arteries with concentric stenosis have demonstrated the presence of platelets and polymorphonuclear leukocytes at the site of the constriction.34 Since PAF may be released from the white blood cells or platelets, the potential for the local generation of PAF is present at the site of an experimental coronary arterial stenosis. This investigation was designed to determine the effect of PAF on coronary blood flow in such a preparation. In summary, PAF given by intracoronary infusion at 10`9 and 10-1 mol/min causes a decrease in systemic blood pressure. PAF can induce cyclic flow variations in a stenosed canine coronary artery. It can also restore cyclic flow variations that have been abolished by a thromboxane synthetase inhibitor (UK38485), a serotonin2 receptor antagonist (ketanserin), or an ce2-adrenergic receptor antagonist (yohimbine). Therefore, the ability of PAF to restore cyclic flow variations is not dependent on thromboxane, serotonin, or a2-adrenergic mechanisms.
